Multivariate analysis of prognostic factors in 516 patients receiving allogeneic transplants for myeloma
| . | HR . | 95% CI . | P . |
|---|---|---|---|
| NRM | |||
| Conditioning | |||
| RIC | 1.0 | Reference | |
| Standard | 1.87 | 1.24-2.81 | .003 |
| Disease status at transplantation | |||
| 1st remission (CR/PR) | 1.0 | Reference | |
| At least 2nd remission or SD | 1.1 | 0.73-1.65 | .04 |
| PD | 1.95 | 1.12-3.40 | |
| Previous transplantation | |||
| None or tandem | 1.0 | Reference | |
| Yes (excluding tandem) | 1.57 | 0.986-2.52 | .06 |
| Relapse | |||
| Conditioning | |||
| RIC | 1.0 | Reference | |
| Standard | 0.51 | 0.35-0.73 | < .001 |
| Disease status at transplantation | |||
| 1st remission (CR/PR) | 1.0 | Reference | |
| At least 2nd remission or SD | 1.49 | 1.06-2.11 | < .001 |
| PD | 2.40 | 1.39-2.88 | |
| Alemtuzumab | |||
| No | 1.0 | Reference | |
| Yes | 2.00 | 1.39-2.88 | < .001 |
| PFS | |||
| Disease status at transplantation | |||
| 1st remission (CR/PR) | 1.0 | Reference | |
| At least 2nd remission or SD | 1.41 | 1.09-1.82 | < .001 |
| PD | 2.36 | 1.7-3.28 | |
| Alemtuzumab | |||
| No | 1.0 | Reference | |
| Yes | 1.92 | 1.48-2.53 | < .001 |
| OS | |||
| Disease status at transplantation | |||
| 1st remission (CR/PR) | 1.0 | Reference | |
| At least 2nd remission or SD | 1.44 | 1.07-1.96 | < .001 |
| PD | 2.35 | 1.02-3.40 | |
| Alemtuzumab | |||
| No | 1.0 | Reference | |
| Yes | 1.82 | 1.07-1.96 | < .001 |
| . | HR . | 95% CI . | P . |
|---|---|---|---|
| NRM | |||
| Conditioning | |||
| RIC | 1.0 | Reference | |
| Standard | 1.87 | 1.24-2.81 | .003 |
| Disease status at transplantation | |||
| 1st remission (CR/PR) | 1.0 | Reference | |
| At least 2nd remission or SD | 1.1 | 0.73-1.65 | .04 |
| PD | 1.95 | 1.12-3.40 | |
| Previous transplantation | |||
| None or tandem | 1.0 | Reference | |
| Yes (excluding tandem) | 1.57 | 0.986-2.52 | .06 |
| Relapse | |||
| Conditioning | |||
| RIC | 1.0 | Reference | |
| Standard | 0.51 | 0.35-0.73 | < .001 |
| Disease status at transplantation | |||
| 1st remission (CR/PR) | 1.0 | Reference | |
| At least 2nd remission or SD | 1.49 | 1.06-2.11 | < .001 |
| PD | 2.40 | 1.39-2.88 | |
| Alemtuzumab | |||
| No | 1.0 | Reference | |
| Yes | 2.00 | 1.39-2.88 | < .001 |
| PFS | |||
| Disease status at transplantation | |||
| 1st remission (CR/PR) | 1.0 | Reference | |
| At least 2nd remission or SD | 1.41 | 1.09-1.82 | < .001 |
| PD | 2.36 | 1.7-3.28 | |
| Alemtuzumab | |||
| No | 1.0 | Reference | |
| Yes | 1.92 | 1.48-2.53 | < .001 |
| OS | |||
| Disease status at transplantation | |||
| 1st remission (CR/PR) | 1.0 | Reference | |
| At least 2nd remission or SD | 1.44 | 1.07-1.96 | < .001 |
| PD | 2.35 | 1.02-3.40 | |
| Alemtuzumab | |||
| No | 1.0 | Reference | |
| Yes | 1.82 | 1.07-1.96 | < .001 |
CR indicates complete remission; PR, partial remission; SD, stable disease; PD, progressive disease.